| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
The primary target of oseltamivir acid-d3 is the influenza virus neuraminidase (NA) enzyme, the same target as the parent compound oseltamivir. Neuraminidase is a surface glycoprotein of influenza viruses that cleaves sialic acid residues, facilitating viral release from infected cells. Inhibition of neuraminidase prevents viral release and spread, reducing the duration and severity of influenza illness. The deuterated form has the same mechanism as the parent compound.
|
|---|---|
| ln Vitro |
In vitro antiviral activity of oseltamivir acid-d3 is expected to be identical to that of oseltamivir carboxylate. Oseltamivir carboxylate potently inhibits influenza virus neuraminidase, with IC₅₀ values in the low nanomolar range against influenza A and B viruses. The compound is active against both seasonal and pandemic influenza strains. Oseltamivir acid-d3 is used as an internal standard in analytical methods rather than for biological activity studies.
|
| ln Vivo |
In vivo efficacy of oseltamivir acid-d3 is not studied as a therapeutic agent; the parent prodrug oseltamivir phosphate is the clinically used formulation. Oseltamivir has demonstrated efficacy in reducing the duration of influenza symptoms, reducing complications, and preventing influenza in clinical trials. The deuterated form is used in bioanalytical methods for quantifying oseltamivir and its metabolite in biological samples. Oseltamivir acid-d3 serves as a stable isotope-labeled internal standard.
|
| Enzyme Assay |
For analytical method development, oseltamivir acid-d3 is used as an internal standard for LC-MS/MS quantification of oseltamivir and oseltamivir carboxylate in plasma, serum, or other biological matrices. The deuterated compound has identical chromatographic and mass spectrometric properties to the unlabeled compound but can be distinguished by its mass shift. Standard protocols for bioanalytical method validation are followed according to regulatory guidelines.
|
| Cell Assay |
Oseltamivir acid-d3 is used in bioanalytical laboratories rather than in cell-based studies. For cell-based studies of antiviral activity, oseltamivir carboxylate is used. Standard protocols for neuraminidase inhibition assays involve incubating the compound with influenza virus neuraminidase and a fluorescent substrate (e.g., MUNANA). Fluorescence is measured, and IC₅₀ values are calculated. For antiviral assays, MDCK cells are infected with influenza virus and treated with the compound.
|
| Animal Protocol |
Oseltamivir acid-d3 is not used in in vivo animal studies as a therapeutic agent. The parent compound oseltamivir has been studied in animal models of influenza infection, including mice and ferrets. The deuterated form is used in pharmacokinetic studies as an internal standard for the quantification of oseltamivir and its metabolites in animal samples. Standard protocols for animal pharmacokinetic studies can be adapted.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of oseltamivir acid-d3 are identical to those of oseltamivir carboxylate. Oseltamivir phosphate is well absorbed after oral administration and is rapidly converted by hepatic esterases to the active metabolite oseltamivir carboxylate. The active metabolite has a half-life of approximately 6-10 hours and is eliminated primarily by renal excretion. Specific PK parameters have been extensively characterized.
|
| Toxicity/Toxicokinetics |
The toxicological profile of oseltamivir acid-d3 is identical to that of oseltamivir. Oseltamivir has a favorable safety profile based on extensive clinical data. Common adverse effects include nausea, vomiting, and headache. Rare but serious adverse effects include neuropsychiatric events. The compound is contraindicated in patients with severe renal impairment. Comprehensive toxicological data are available from regulatory submissions.
|
| References |
|
| Additional Infomation |
Oseltamivir acid-d3 is a stable isotope-labeled internal standard used in analytical chemistry for the quantification of oseltamivir and its active metabolite in biological samples. The deuterated compound is used in bioanalytical method development and validation, pharmacokinetic studies, and therapeutic drug monitoring. Oseltamivir (the parent prodrug) is an FDA-approved drug for the treatment and prevention of influenza. Oseltamivir acid-d3 is not a therapeutic agent and is not approved for clinical use.
|
| Molecular Formula |
C14H21D3N2O4
|
|---|---|
| Molecular Weight |
287.37
|
| Exact Mass |
287.192
|
| CAS # |
1242184-43-5
|
| Related CAS # |
Oseltamivir acid;187227-45-8;Oseltamivir acid hydrochloride;1415963-60-8
|
| PubChem CID |
4631786
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.347
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
20
|
| Complexity |
391
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCC(CC)OC1C=C(CC(C1NC(=O)C)N)C(=O)O
|
| InChi Key |
NENPYTRHICXVCS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H24N2O4/c1-4-10(5-2)20-12-7-9(14(18)19)6-11(15)13(12)16-8(3)17/h7,10-13H,4-6,15H2,1-3H3,(H,16,17)(H,18,19)
|
| Chemical Name |
4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4798 mL | 17.3992 mL | 34.7983 mL | |
| 5 mM | 0.6960 mL | 3.4798 mL | 6.9597 mL | |
| 10 mM | 0.3480 mL | 1.7399 mL | 3.4798 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
